Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Saudi Arabia flag Saudi Arabia · Delayed Price · Currency is SAR
151.70
+0.70 (0.46%)
At close: Dec 4, 2025
-1.11%
Market Cap 10.62B
Revenue (ttm) 1.46B
Net Income (ttm) 447.34M
Shares Out 70.00M
EPS (ttm) 6.39
PE Ratio 23.74
Forward PE 21.34
Dividend 3.06 (2.02%)
Ex-Dividend Date Jul 29, 2025
Volume 45,721
Average Volume 39,339
Open 150.90
Previous Close 151.00
Day's Range 149.50 - 152.50
52-Week Range 134.00 - 183.80
Beta 0.74
RSI 51.52
Earnings Date Feb 24, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. The company offers human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosme... [Read more]

Sector Healthcare
Founded 1994
Country Saudi Arabia
Stock Exchange Saudi Stock Exchange
Ticker Symbol 4015
Full Company Profile

Financial Performance

In 2024, TADAWUL:4015's revenue was 1.32 billion, an increase of 19.77% compared to the previous year's 1.10 billion. Earnings were 356.52 million, an increase of 21.93%.

Financial Statements

News

There is no news available yet.